Tumors Show Heightened DNA Methylation Variability Tied to Instability and Worse Survival

Tumors carry more than just abnormal average levels of DNA methylation. A new study published in Epigenetics & Chromatin reports that the variability of methylation across the genome—how much methylation states fluctuate at specific regions within and between tumors—constitutes a distinct dimension of cancer epigenomes, and that tumors with high variability fare markedly worse in clinical outcomes. The analysis, led by Djansel Bukovec, Blagojche Gjorgjioski, Monika Simjanoska Misheva and Goran Kungulovski, systematically quantified this variability across 16 cancer types using paired tumor–normal DNA methylation profiles.

The researchers measured variability in three complementary ways per sample: the proportion of intermediately methylated sites (PIM), genome-wide Shannon entropy, and a DNA methylation-based stemness index. These metrics were benchmarked against both bulk and single-cell methylome data. Across all cancer types examined, tumor samples consistently showed higher DNA methylation variability than matched normal tissues, reflected by increased dispersion and wider interquartile ranges. The pan-cancer pattern held up under complementary statistical approaches and multiple modes of data representation, suggesting it is a robust feature rather than an artifact of any single analytical method.

Where in the genome this variability concentrates proved telling. Pan-cancer variably methylated regions were depleted in promoters and enriched in so-called open sea regions, in heterochromatic domains decorated with the H3K27me3 histone mark and repressed by the PRC2 complex, and at enhancers. These regions preferentially contained motifs for transcription factors involved in developmental regulation. According to the authors, this organization reflects disrupted maintenance of epigenomic states, which may enable adaptation to the tumor microenvironment, phenotypic plasticity, invasion, disease progression, and treatment resistance.

The study then connected variability to genomic instability. Elevated DNA methylation variability—captured by higher PIM, entropy, and stemness scores—was associated with increased genomic instability, manifested as higher aneuploidy, increased DNA break points, a greater fraction of the genome altered, and increased tumor mutational burden. Variability was also linked to aggressive tumor features, including lymph node involvement, post-therapy neoplasm events, and elevated hypoxia scores. The associations were assessed after the variability metrics had been evaluated against genomic features, transcriptional and chromatin regulators, and biological processes.

Most strikingly, the variability measures tracked with patient prognosis. Tumors with high DNA methylation variability exhibited significantly worse overall survival, progression-free survival, and disease-free survival. The authors conclude that DNA methylation variability is a pervasive and relevant feature of tumor epigenomes, reflecting both epigenetic and genetic instability as well as tumor aggressiveness. Because the work is observational in nature, the findings establish associations between variability, instability, and outcomes rather than demonstrating that variability causes the poorer clinical course.

The study’s scope deserves emphasis. It analyzed existing paired tumor–normal methylation profiles across 16 cancer types rather than following patients prospectively, and the variability metrics were computed from bulk tumor data with validation against single-cell methylome data. The paper, published open access on 29 September 2026, is being shared early as a peer-reviewed, accepted version of record, subject to further edits. Within those limits, the work offers a systematic, pan-cancer map of where methylation states become unstable in cancer and how that instability relates to the genomic and clinical features of aggressive disease.

Subject of Research: DNA methylation variability in tumor epigenomes and its links to genomic instability, aggressiveness, and survival

Article Title: DNA methylation variability defines a fundamental dimension of tumor epigenomes linked to genomic instability, tumor aggressiveness, and clinical outcomes

Article References: Bukovec, D., Gjorgjioski, B., Misheva, M. S., & Kungulovski, G. (2026). DNA methylation variability defines a fundamental dimension of tumor epigenomes linked to genomic instability, tumor aggressiveness, and clinical outcomes. Epigenetics & Chromatin. https://doi.org/10.1186/s13072-026-00704-y

Image Credits: AI Generated

DOI: 10.1186/s13072-026-00704-y

Keywords: DNA methylation, tumor epigenome, genomic instability, cancer epigenetics, PRC2, aneuploidy, tumor mutational burden, hypoxia, stemness index, survival outcomes, pan-cancer analysis, epigenetic variability